Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial

Main Article Content

Bruce Strober
Yayoi Tada
Ulrich Mrowietz
Mark Lebwohl
Peter Foley
Richard G Langley
Jonathan Barker
Maggie Wang
Veerle Vanvoorden
Balint Szilagyi
Valerie Ciaravino
Carle Paul

Keywords

bimekizumab, biologic, psoriasis, BE BRIGHT, moderate to severe, clinical trial

Abstract

N/A

References

1. Yiu ZZN et al. Br J Dermatol 2020;183:294–302

2. Warren RB et al. N Engl J Med 2021;385:130–41

3. Reich K et al. Lancet 2021;397:487–98

4.Gordon KB et al. Lancet 2021;397:475–86

5. Strober B et al. Presented at EADV 2021; P1317

Most read articles by the same author(s)

<< < 3 4 5 6 7 8 9 10 > >>